Breathwork: Pulmonary Hypertension with Professor Sean Gaine (Part 2)

This week, we’re joined by Professor Seán Gaine, Ireland’s foremost expert in pulmonary hypertension. In this insightful episode, he shares his expert perspective on the diagnosis, classification, and clinical presentation of the condition, as well as the latest advances in treatment. A must-listen for all healthcare professionals, Professor Gaine also discusses when to suspect pulmonary hypertension and highlights the nuances in the management of patients with pulmonary hypertension. Don’t miss this opportunity to learn from a global leader in the field. Chapters 0:52 Rapid fire round on pulmonary hypertension 01:42 Definition of pulmonary hypertension 02:08 Signs and symptoms of pulmonary hypertension 02:56 Five groups of pulmonary hypertension 03:33 Group 1 pulmonary hypertension: Pulmonary arterial hypertension 04:34 Group 2 pulmonary hypertension: Left heart disease 05:23 Group 3 pulmonary hypertension: Chronic lung disease/hypoxia 05:58 Group 4 pulmonary hypertension: Pulmonary vascular obstruction 06:30 Group 5 pulmonary hypertension: Miscellaneous 07:25 Referral to the national pulmonary hypertension centre: right heart catheterisation 09:37 Work up in the pulmonary hypertension clinic 11:06 Risk stratification in pulmonary hypertension 12:06 Diagnostic criteria pulmonary hypertension Dynamic testing right heart catheterisation: Cardiopulmonary exercise testing Reliability of right heart catheterisation Treatment algorithm in pulmonary arterial hypertension Tripple therapy for high risk patients Double combination therapy for non-high risk patients Fourth treatment pathway, Quadruple therapy?: Sotatercept - an activin scavenger Treatment options for groups 4 pulmonary hypertension: Balloon pulmonary angioplasty Treatment options for groups 2, 3 and 5 Side effects of triple therapy Lung transplant in pulmonary hypertension: Double or single lung transplant Pitfalls in the acute management of patients with pulmonary hypertension Interpretation of the B Natriuretic Peptide level Medications contraindicated pulmonary hypertensions Outcomes in pulmonary hypertension Take home message on pulmonary hypertension Show Notes - https://lumen5.com/user/edofficer/sotatercept-emergin-d5jg6/ - Irish Thoracic Society Flashcard Pulmonary Hypertension https://irishthoracicsociety.com/wp-content/uploads/2021/06/5.-Pulmonary-Hypertension.pdf - Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest 2021; 159: 337–346. - Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal. 2022:2200879. DOI: https://doi.org/10.1183/13993003.00879-2022 - Chin KM, Gaine SP, Gerges C, Jing Z-C, Mathai SC, Tamura Y, et al. Treatment algorithm for pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4):2401325. DOI: https://doi.org/10.1183/13993003.01325-2024 - Hoeper, M.M., Badesch, D.B., Ghofrani, H.A., Gibbs, J.S.R., GombergMaitland, M., McLaughlin, V.V. et al. (2023) ‘Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension’, New England Journal of Medicine, 388(17), pp. 1478–1490. Available at: https://doi.org/10.1056/NEJMoa2213558 - Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987-2000. DOI: 10.1056/NEJMoa2415160